|
|
EIGHTH INTERNATIONAL PHARMACEUTICAL COMPLIANCE CONGRESS
May 5 - 7, 2014
|
ATTEND ONSITE
|
WEBCAST ATTENDANCE
|
Conrad Dubai
Dubai, United Arab Emirates |
In your own office or home live via the Internet with 24/7 access for 6 months
|
|
|
|
KEYNOTE SPEAKERS
|
Michel Ballieu
Chief Executive Officer, European CanCer Organisation, Brussels, Belgium |
Isabel Bardinet
Chief Executive Officer, European Society of Cardiology, Sophia Antipolis, France |
Richard Bergström
Director General, European Federation of the Pharmaceutical Industries and Associations (EFPIA), Former Director General, LIF Sweden, Brussels, Belgium
|
Julie Bonhomme, Esq.
Legal and Compliance Manager, Legal and Compliance Department, LEEM, Paris, France |
Ingrid Callies, LLM, PhD
Permanent Secretary of the CODEEM (the ethics committee of the pharmaceutical industry), French Code Authority, Leem, Paris, France |
Holger Diener, PhD
Managing Director, Association of Voluntary Self-Regulation for the Pharmaceutical Industry, Berlin, Germany
|
Debra Christenson Forster, Esq.
Global Compliance Officer, Novartis Pharma AG, Former Executive Director, Marketing and Sales Compliance, Boehringer Ingelheim, Basel, Switzerland |
Jane Griffiths, PhD
Company Group Chairman Janssen, Europe, Middle East and Africa (EMEA), Janssen-Cilag Ltd., EMEA; Chairman, EFPIA Executive Committee; Chairman, PhRMA Europe Committee, Buckinghamshire, UK |
Dr. Yacoub Haddad
Chair, Pharmaceutical Research and Manufacturers Association, Gulf (PhRMAG), Government Affairs Director MEAP Region, Abbvie, Dubai, UAE
|
Parichay Mittal
Director - Compliance, South Asia, Compliance & Business Integrity Department, Sanofi, Member, Working Group on Ethics and Compliance, Organization of Pharmaceutical Producers of India (OPPI), Mumbai, India |
Arthur Muratyan, Esq.
Secretary General, International Society of HealthCare Ethics and Compliance Professionals (ETHICS), Former Vice President-Head of Legal Corporate, and Global Compliance Officer, Sanofi, Paris, France |
Jean-Claude Najar, LLM
Member, Curtis, Mallet-Prevost, Colt & Mosle LLP, Lecturer, Sciences Po Law School and HEAD Law School, Former General Counsel EMEA, GE Medical Systems (now GE Healthcare), Paris, France
|
Prof. Dr. iur. Mark Pieth
Professor of Criminal Law and Criminology, University of Basel, Former Head of Section, Economic and Organised Crime, Swiss Federal Office of Justice, Former Chair, OECD Working Group on Bribery in International Business Transactions, Basel, Switzerland |
Christine Sainvil
Compliance Officer, Eucomed, Brussels, Belgium |
Heather Simmonds
Director and Chair, Code of Practice Panel, Prescription Medicines Code of Practice Authority, London, UK
|
Carin R. Smand, MSc
Managing Director, European Hematology Association, The Hague, The Netherlands |
Peter Solmssen
Former General Counsel and Head of Legal and Compliance and Member, Managing Board, Siemens AG, Former General Counsel Germany and Lead Lawyer Commercial Finance Europe, General Electric Company, Munich, Germany |
Jose F. Zamarriego Izquierdo
Director Unidad de Supervision Deontologica, FARMAINDUSTRIA, Madrid, Spain
|
|
|
THE CONGRESS FEATURES EU COMPLIANCE DEVELOPMENTS,
WITH SPECIAL REPORTS FROM CEE, MEA AND INDIA
|
|
|
FEATURING A FOCUS ON NEW PHARMA BUSINESS MODELS
AND RESULTING COMPLIANCE CHALLENGES
|
- Changing Business Models:
- Context:
- Rising Costs
- Decline of Blockbuster Model
- Rise of Specialty Care/Biologics
- Industry Trends:
- Consolidation
- Patent Cliff
- Mature Markets
- Growth of Emerging Markets
- Diversification into Diagnostics and Devices, Generics and Consumer Health
- More Partnerships, Collaborations, and Licensing Agreements
- Old Model Centered on Company/HCP Relationship
- New Model in US, ACA, Increased Governmental Funding and Negotiations with Insurers
- New Model Globally, Negotiation with Government
- Emerging of Comparative Effectiveness Research
- New Ethics and Compliance Issues Arise around:
- Market Access, Affordability, Infrastructure and Knowledge in Emerging Markets, Limiting Health Care Systems
- Managing Third Party Relationships, Increased Risk, Less Transparency
- Pricing and Reimbursement; Conditional upon Post Marketing Confirmation of Effectiveness
- Tendering
- R&D; Clinical Trials; Publications
- Medical Education
- New National Anticorruption Initiatives
- Proliferation of Transparency Initiatives
- The Role of Compliance Codes
|
|
|
|
FEATURING IFPMA CODE WORKSHOP AND ETHICAL PROMOTION ROUNDTABLE
|
The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is offering an independent IFPMA CODE WORKSHOP: HANDS-ON COMPLIANCE TRIANING on Sunday, May 4, 2014.
|
 |
Tamara Music, Manager, Influenza Vaccines & Code Compliance, IFPMA, Geneva, Switzerland (Chair)
|
|
|
A MIDDLE EAST/AFRICA (MEA) REGIONAL COMPLIANCE ROUNDTABLE
|
|
Sponsored by International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and Pharmaceutical Research and Manufacturers Association, Gulf (PhRMAG)
|
|
|
|
|
On the morning of Monday, May 5, 2014 the following will co-chair a MEA Regional Compliance Roundtable:
|
 |
Nabil Daoud, MA, Vice President and Area Director TMEA-CIS, Eli Lilly, Chair, MEA Regional Ethics Group (LERB), Dubai, United Arab Emirates
|
|
|
|
Dr. Yacoub Haddad, Chair, Pharmaceutical Research and Manufacturers Association, Gulf (PhRMAG), Government Affairs Director MEAP Region, Abbvie, Dubai, UAE
|
|
|
THE CONGRESS THE FOLLOWING PLENARY SESSIONS
|
|
|
- Congress Vision and Overview
- MEA Compliance Best Practices Overview
- India Compliance Best Practices Overview
- Global Transparency Regulatory Update Roundtable
- Communicating with Health Care Professionals re Participation in Transparency Programs
- The Perspectives of Leading NGOs re Pharma Ethical and Compliance Regimes
- Medical Device Compliance and Ethics Issues Update
- Emerging Compliance Issue: R&D, Clinical Trials, Post Marketing Studies and Publications
- Emerging Compliance: Market Access, Pricing, Reimbursement and Tendering
- Emerging Compliance Issue: Medical Education and the Thin Line between Information and Promotion
- Roundtable on Current Challenges and New National Anticorruption Initiatives
- The Role of Ethics in the Compliance Decision Making Process
- The Worldwide Enforcement Environment for Pharma and Medical Devices
- Transforming the Compliance Profession
- Global Compliance Code Update
|
|
|
AND THE FOLLOWING IN-DEPTH
MINI SUMMITS
|
- Training on Compliance and Ethics Basics I
- Annual MEA Compliance and Ethics Update
- Global Compliance Auditing and Monitoring Best Practices
- R&D, Clinical Trials, Transparency, Post Marketing Studies and Publications
- Advanced Issues in Global Transparency , Disclosure and Aggregate Spend Compliance
- Training on Compliance and Ethics Basics II
- Indian Compliance Best Practices Roundtable
- Medical Education and the Thin Line between Information and Promotion
- Global Fair Market Value Update
- Congresses and the Realities of Cross-border Confluence
- Training on Compliance and Ethics Basics III
- Annual Central and Eastern Europe Compliance Update
- Lessons from the Global Medical Device Sector Compliance Issues
- Advanced Issues in Global Anticorruption Compliance
- Public Procurement, Tendering, Reimbursement and Pricing Update
- Managing the Compliance Function being both Small and Global
- Turkish Compliance Roundtable
- Using Data Analytics and Going Beyond Policy Compliance
- The Business Benefits of Compliance
|
|
|
|
FEATURED FACULTY
|
Ted Acosta, Esq.
Principal, Fraud Investigation & Dispute Services, EY; Former Senior Counsel, Office of Inspector General, United States Department of Health and Human Services, New York, NY, USA and Paris, France |
Dr. Amin Al Amiri
Assistant Undersecretary, Medical Practice and Licenses, Ministry of Health, UAE, Dubai, UAE |
Timothy S. Ayers, Esq.
Principal, Porzio, Bromberg & Newman, PC, Vice President, Porzio Life Sciences, Former Vice President and Chief Compliance Officer, Dendreon Corporation, Morristown, NJ, USA
|
Yogesh Bahl, MBA
Life Sciences Practice Lead, Financial Advisory Services, AlixPartners, LLP, New York, NY |
Hulya Baran
Director, Ethics and Compliance TMEA - CIS, Eli Lilly and Company, Istanbul, Turkey |
Carsten Blaesberg
Chief Consultant, Lif Denmark, The Danish Association of the Pharmaceutical Industry, Copenhagen, Denmark
|
Hein van den Bos, Esq.
Counsel, Hogan Lovells International LLP, Amsterdam, Netherlands |
Sarah Chopp
Corporate Counsel, Government Investigations, Pfizer, Inc., New York, NY |
Kris L. Curry
Principal, Fraud Investigation & Dispute Services, EY, Philadelphia, PA, USA
|
Nabil Daoud, MA
Vice President and Area Director TMEA-CIS, Eli Lilly, Chair, MEA Regional Ethics Group (LERB), Dubai, United Arab Emirates |
Sacha D'Ecclesiis, Esq.
Senior Associate, Hogan Lovells, Rome, Italy |
Peter Dieners, Esq.
Partner, Clifford Chance, Düsseldorf, Germany
|
Sue Egan
Director and Principal Consultant, Sue Egan Associates, Former Vice President Compliance, AstraZeneca, Great Missenden, Buckinghamshire, UK |
Walid Fahim
Regional Compliance Manager, Turkey, South Africa & Middle East, EMEA, Emerging Markets, Covidien, Dubai, United Arab Emirates |
Saad Fahmy
Compliance Director, Middle East & Pakistan, Sanofi, Former Compliance Officer (Gulf, Saudi, Arabia & Developing Markets), Merck, Dubai, United Arab Emirates
|
Pascale Feghali
Ethics & Compliance Director, Middle East & Egypt, Eli Lilly, Beirut, Lebanon |
George Fife
Executive Director, EMEA Compliance & Ethics, Bristol-Myers Squibb, Paris, France |
Gary F. Giampetruzzi, Esq.
Partner, Paul Hastings; Former Vice President and Assistant General Counsel and Head of Government Investigations, Pfizer Inc., New York, NY, USA
|
Ulf Grundmann, JD
Partner, King & Spalding, Lecturer, Frankfurt School of Finance and Management and Deutsche Anwalts Akademie, Author, Guide to EU Pharmaceutical Regulatory Law, Frankfurt, Germany |
Meltem Ozker Gunduz
Legal Affairs and Compliance Director, Business Area Near East, Novo Nordisk, Istanbul, Turkey |
Thomas A. Gunning, Esq.
Senior Vice President and General Counsel, Prescription Medicines' Division, Merck KGaA, Darmstadt, Germany
|
Antoinette Gutierrez-Crespin
Partner, Fraud Investigation & Dispute Services, EY, Paris, France |
Rozalia Gyulai
Regional Compliance Manager, AbbVie, Former Regulatory Manager, Pfizer, Budapest, Hungary |
Tareq Haddad
Regional Strategic Planning Manager, PwC, United Arab Emirates
|
Joe Henein
President and Chief Executive Officer, NewBridge Pharmaceuticals, Former Regional Managing Director, Middle East, and North Africa, Wyeth Pharmaceuticals, Dubai, United Arab Emirates |
Sally Jeffery, MBA
Partner, PwC, Dubai, UAE |
Swee Kheng Khor, MD
Associate Director, Office of Ethics & Compliance, Middle East & Pakistan, AbbVie BioPharmaceutical, GmBH, Dubai, United Arab Emirates
|
Dr. Marcel Koerting, LLM
Senior Legal & Compliance Counsel, Novo Nordisk Health Care AG, Zurich, Switzerland |
Keith M. Korenchuk, JD, MPH
Partner, Arnold & Porter LLP, Washington, DC, USA |
Daniel A. Kracov, Esq.
Partner and Head, FDA and Healthcare Practice, Arnold & Porter, Washington, DC, USA
|
Michael K. Loucks, Esq.
Partner, Skadden Arps LLP, Former Acting United States Attorney, District of Massachusetts, Washington, DC, USA |
Abdul Luheshi, MBA
Vice President Health Care Compliance, Asia Pacific, Johnson & Johnson, Former Co-chair, Asia Pacific Pharma Compliance Congress, Singapore |
Rajiv Malhotra
Senior Manager Compliance, Biogen Idec, Former Ethics and Compliance Officer, Eli Lilly and Company (India) Pvt Ltd, Gurgaon, India
|
Paul J. Melling, Esq.
Founding Partner, Baker & McKenzie - CIS, Limited, Moscow, Russia |
Laura Nassar
Regional Pharma HCC Officer Emerging Markets, Johnson & Johnson, Beirut, Lebanon |
Dr. Ima Parrondo
Health Care Compliance Lead Officer Pharmaceuticals, EMEA-C, HCC&P, Johnson & Johnson, Madrid, Spain
|
Minal Patel
Compliance Officer, Pharmaceuticals & Consumer, South Africa & Sub Saharan Africa, Johnson & Johnson, Johannesburg, South Africa |
Piergiorgio Pepe, LLB, LLM
Office of Ethics & Compliance Regional Director, Eastern Europe-Middle East & Africa, Abbvie Pharmaceuticals Europe HQ, Rungis, France |
Dr. Gudula Petersen
Chief Compliance Officer Europe & Australia, Grunenthal, Aachen, Germany
|
Nathalie Raynaud
Corporate Compliance Director, Global Compliance & Business Integrity Department, Sanofi, Paris, France |
Brian Riewerts
Principal, Global Governance, Risk and Compliance Leader, Pharmaceutical and Life Sciences Advisory, PwC, Baltimore, MD, USA |
Vivian Robinson, Esq.
Partner, McGuire Woods, Former General Counsel of the UK Serious Fraud Office, Former Head, QEB Hollis Whiteman Chambers, Recorder of the Crown Court and Treasurer of Inner Temple, London, UK
|
Jeff Rosenbaum
Vice President, Chief Compliance Officer, Vertex Pharmaceuticals, Former Executive Director, Global Head of Ethics & Compliance Novartis Oncology, Boston, MA, USA |
Christian-Claus Roth
Head of Congresses and Conventions, Novartis Pharma, Co-President, International Pharmaceutical Congress Advisory Association (IPCAA), Berne, Switzerland |
Fabien Roy
Associate, Hogan Lovells, Brussels, Belgium
|
Christine Sainvil
Compliance Officer, EthicalMedTech, Brussels, Belgium |
Sandeep Seth, LLB
Director - Compliance, MSD Pharmaceuticals Pvt. Ltd. (Merck), Mumbai, India |
Jade L. Shields
Chief Compliance Officer and Associate Vice President, Ferring Pharmaceuticals, Parsippany, NJ, USA
|
Abdulrahman Al Sultan
Executive Director of Communication & Awareness, Saudi Food & Drug Authority, Riyadh, Saudi Arabia |
Tahan (Tom) A. Thraya, Esq.
Partner, Baker & McKenzie LLP, Abu Dhabi, UAE |
Joseph B. Tompkins, Jr.
Partner, Sidley Austin LLP, Former Deputy Chief of the Fraud Section, Criminal Division, United States Department of Justice, Washington, DC, USA
|
Magalie Treguer, Esq.
Senior Director, Corporate Compliance and Regional Compliance Officer for Europe and Canada, Biogen Idec, International GmbH, Zürich, Switzerland |
Ramesh Varadarajan
Local Compliance Officer, AstraZeneca Pharma India Ltd., Bangalore, India
|
Vincent M. Walden, CFE, CITP
Partner, Fraud Investigation & Dispute Services, EY, New York, NY, USA |
Mariusz Witalis, CFE, CIA
Partner, Fraud Investigation & Dispute Services, EY, Warsaw, Poland
|
|
|
|
|
|
|
BROCHURE NOW AVAILABLE
|
Click here to download
the brochure.
|
|
|
|
ASSOCIATION REGISTRATION DISCOUNT
|
Click here for Special ETHICS/PCF/IFPMA/EFPIA/ PhRMAG/OPPI/USIBC Member Rate.
|
|
|
|
|
SPONSORED BY:
|
|
|
|
CO-SPONSORED BY:
|
|
|
|
CONGRESS CO CHAIRS
|
Ann Beasley Bacon
Senior Vice President and Chief Compliance Officer, Biogen Idec, Board Member and Co-chair, Strategic Committee, International Society of Healthcare, Ethics and Compliance Professionals (ethics), Cambridge, MA, USA
|
Dr. Michael Bartke
Director Compliance Management, DAIICHI SANKYO EUROPE GmbH, Co-chair, EFPIA Compliance Workgroup, Munich, Germany
|
Dominique Laymand
Vice President Compliance & Ethics EMEA, (Europe, Middle-East, Africa, Russia and Turkey), Bristol-Myers Squibb, President, International Society of Healthcare, Ethics and Compliance Professionals (ethics), Paris, France
|
Roeland Van Aelst
Vice President Health Care Compliance Medical Devices & Diagnostics EMEA-C, HCC&P, Johnson & Johnson, Board Member and Co-chair, Strategic Committee, International Society of Healthcare, Ethics and Compliance Professionals (ethics), Chairman, EUCOMED Compliance Network, Brussels, Belgium
|
|
|
|
MEDIA PARTNER
|
|
|
OUTREACH PARTNER
|
|
|
|
CONTINUING EDUCATION CREDITS
|
Compliance Professionals: Approved for up to 18.4 Compliance Certification Board CCB Credits.
Accounting Professionals: Approved for up to 19 NASBE CPE credits.
Attorneys:
- Approved to offer a maximum of 16.0 Hours of California CLE Credits.
- Approved to offer a maximum of 15.0 Hours of Pennsylvania CLE Credits, including 2.0 Hours for Ethics CLE.
- Approved to offer a maximum of 16.0 Hours of Texas CLE Credits.
Click here for more information.
|
|
GRANTORS:
|
|
DIAMOND
|
|
|
PLATINUM
|
|
|
GOLD
|
|
|
BRONZE
|
|
|
FEATURING VIDEO PRESENTATIONS FROM PAST CONGRESSES:
|
|
2013 Seventh International Pharma Congress Keynote Address by
|
Huguette Labelle, CC, PhD, LLD
Chair, Transparency International, Companion of the Order of Canada, Berlin, Germany
|
|
2013 Fourteenth International US Pharma Congress Keynote Address by
|
Brent L. Saunders, JD, MBA
Chief Executive Officer, Forest Laboratories, Former Chief Executive Officer, Bausch + Lomb, Rochester, NY
|
|
2012 Second Asia Pacific Pharma Congress Keynote Address by
|
Mark Mallon, MBA
Regional Vice President Asia Pacific and President China, AstraZeneca, Former Executive Vice-President and Chief Operating Officer, AstraZeneca KK (Japan), Shanghai, China
|
|
2012 Sixth International Pharma Congress Keynote Address by
|
Christopher A. Viehbacher
Chief Executive Officer, Sanofi, Chairman, Genzyme, Paris, France
|
|
2011 Twelfth Pharmaceutical Regulatory Compliance Congress and Best Practices Forum by
|
John C. Lechleiter, PhD
Chairman, President and Chief Executive Officer, Eli Lilly and Company, Chairman-elect, PhRMA, Indianapolis, IN
|
|
2011 Fifth International Pharma Congress Keynote Address by
|
David Brennan
Former Chief Executive Officer, AstraZeneca, President, IFPMA, Past Chairman, PhRMA, London, UK
|
|
OTHER INTERNATIONAL PHARMA CONGRESSES
|
2007 - Brussels
2008 - Paris
2009 - Rome
2010 - Berlin
2011 - Istanbul
2011 - Singapore
2012 - Budapest
2012 - Shanghai
2012 - São Paulo
2013 - Madrid, Spain
2013 - Kuala Lumpur
2014 - Dubai
2014 - Mexico City
|
|
FOLLOW INTERNATIONAL PHARMA CONGRESS ON
|
|
|
INTERNATIONAL PHARMA CONGRESS IS
|
|
|
|
